A phase I trial to evaluate OTX-TKI.
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2017
At a glance
- Drugs OTX-TKI (Primary)
- Indications Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration
- Focus Adverse reactions
- 07 Nov 2017 According to an Ocular Therapeutix media release, Company expects to initiate this trial outside the United States for OTX-TKI in the first half of 2018.
- 08 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Dec 2017, according to an Ocular Therapeutix media release.
- 22 May 2017 New trial record